Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias

被引：12

作者：

Brendel, J ^{[1
]}

Peukert, S ^{[1
]}

机构：

[1] Aventis Pharma Deutschland GMBH, Med Chem, D-65926 Frankfurt, Germany

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2002年 / 12卷 / 11期

关键词：

arrhythmia; atrial fibrillation; IKur; Kv1.5; potassium channel blockers;

D O I：

10.1517/13543776.12.11.1589

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Atrial arrhythmias are a common problem in cardiological practice. Despite the availability of several antiarrhythmic drugs there is a medical need for safer and more efficient treatments. The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. This review summarises patents claiming such compounds.-The chemistry and biological data disclosed in these patents are discussed in light of recent work demonstrating the antiarrhythmic effects of Kv1.5 blockers in vivo.

引用

页码：1589 / 1598

页数：10

共 81 条

[1] Differences between outward currents of human atrial, and subepicardial ventricular myocytes [J].

Amos, GJ ;

Wettwer, E ;

Metzger, F ;

Li, Q ;

Himmel, HM ;

Ravens, U .

JOURNAL OF PHYSIOLOGY-LONDON, 1996, 491 (01) :31-50

[2]

ASHCROFT MA, 2000, ION CHANNELS DIS, P97

[3]

ATWAL KS, 2001, Patent No. 0140231

[4]

AVENTIS SA, 2002, Patent No. 0244137

[5]

AVENTIS SA, 2001, Patent No. 0100573

[6]

AVENTIS SA, 2001, Patent No. 0125189

[7]

AVENTIS SA, 2002, Patent No. 0246162

[8] Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes [J].

Bachmann, A ;

Gutcher, I ;

Kopp, K ;

Brendel, J ;

Bosch, RF ;

Busch, AE ;

Gögelein, H .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 364 (05) :472-478

[9]

Baker R.K., 2000, Patent, Patent No. [00/25774, 0025774]

[10]

Bochis R.J., 1996, PCT Int. Appl, Patent No. 9625936

← 1 2 3 4 5 6 7 8 9 →